270 related articles for article (PubMed ID: 23772842)
1. β-Adrenoceptor blockers and pulmonary function in the general population: the Rotterdam Study.
Loth DW; Brusselle GG; Lahousse L; Hofman A; Leufkens HG; Stricker BH
Br J Clin Pharmacol; 2014 Jan; 77(1):190-200. PubMed ID: 23772842
[TBL] [Abstract][Full Text] [Related]
2. Cardioselective beta-blocker use in patients with reversible airway disease.
Salpeter S; Ormiston T; Salpeter E
Cochrane Database Syst Rev; 2001; 2002(2):CD002992. PubMed ID: 11406056
[TBL] [Abstract][Full Text] [Related]
3. Cardioselective beta-blockers for reversible airway disease.
Salpeter S; Ormiston T; Salpeter E
Cochrane Database Syst Rev; 2002; (1):CD002992. PubMed ID: 11869646
[TBL] [Abstract][Full Text] [Related]
4. Cardioselective beta-blockers for reversible airway disease.
Salpeter S; Ormiston T; Salpeter E
Cochrane Database Syst Rev; 2002; (4):CD002992. PubMed ID: 12519582
[TBL] [Abstract][Full Text] [Related]
5. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis.
Salpeter SR; Ormiston TM; Salpeter EE; Poole PJ; Cates CJ
Respir Med; 2003 Oct; 97(10):1094-101. PubMed ID: 14561016
[TBL] [Abstract][Full Text] [Related]
6. Cardioselective beta-blockers for chronic obstructive pulmonary disease.
Salpeter SS; Ormiston T; Salpeter E; Poole P; Cates C
Cochrane Database Syst Rev; 2002; (2):CD003566. PubMed ID: 12076486
[TBL] [Abstract][Full Text] [Related]
7. Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease.
Fortis S; Comellas A; Make BJ; Hersh CP; Bodduluri S; Georgopoulos D; Kim V; Criner GJ; Dransfield MT; Bhatt SP;
Ann Am Thorac Soc; 2019 Jul; 16(7):826-835. PubMed ID: 30908927
[No Abstract] [Full Text] [Related]
8. Association between lutein intake and lung function in adults: the Rotterdam Study.
Melo van Lent D; Leermakers ET; Hofman A; Stricker BH; Brusselle GG; Franco OH; Lahousse L; Kiefte-de Jong JC
Br J Nutr; 2017 Mar; 117(5):720-730. PubMed ID: 28376947
[TBL] [Abstract][Full Text] [Related]
9. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.
Salpeter SR; Ormiston TM; Salpeter EE
Ann Intern Med; 2002 Nov; 137(9):715-25. PubMed ID: 12416945
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease.
Oda N; Miyahara N; Ichikawa H; Tanimoto Y; Kajimoto K; Sakugawa M; Kawai H; Taniguchi A; Morichika D; Tanimoto M; Kanehiro A; Kiura K
Int J Chron Obstruct Pulmon Dis; 2017; 12():1119-1124. PubMed ID: 28435245
[TBL] [Abstract][Full Text] [Related]
11. Cardioselective beta-blockers for chronic obstructive pulmonary disease.
Salpeter S; Ormiston T; Salpeter E
Cochrane Database Syst Rev; 2005 Oct; 2005(4):CD003566. PubMed ID: 16235327
[TBL] [Abstract][Full Text] [Related]
12. Use of cardioselective β-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials.
Ni Y; Shi G; Wan H
J Int Med Res; 2012; 40(6):2051-65. PubMed ID: 23321161
[TBL] [Abstract][Full Text] [Related]
13. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study.
Wijnant SRA; De Roos E; Kavousi M; Stricker BH; Terzikhan N; Lahousse L; Brusselle GG
Eur Respir J; 2020 Jan; 55(1):. PubMed ID: 31601717
[TBL] [Abstract][Full Text] [Related]
14. Dietary intake of fatty acids and its relationship with FEV
Jiménez-Cepeda A; Dávila-Said G; Orea-Tejeda A; González-Islas D; Elizondo-Montes M; Pérez-Cortes G; Keirns-Davies C; Castillo-Aguilar LF; Verdeja-Vendrell L; Peláez-Hernández V; Sánchez-Santillán RN
Clin Nutr ESPEN; 2019 Feb; 29():92-96. PubMed ID: 30661707
[TBL] [Abstract][Full Text] [Related]
15. Cut-off value of FEV1/FEV6 as a surrogate for FEV1/FVC for detecting airway obstruction in a Korean population.
Chung KS; Jung JY; Park MS; Kim YS; Kim SK; Chang J; Song JH
Int J Chron Obstruct Pulmon Dis; 2016; 11():1957-63. PubMed ID: 27578970
[TBL] [Abstract][Full Text] [Related]
16. Use of cardioselective β-blockers and overall death and cardiovascular outcomes in patients with COPD: a population-based cohort study.
Dong YH; Chang CH; Wu LC; Lai MS
Eur J Clin Pharmacol; 2016 Oct; 72(10):1265-1273. PubMed ID: 27444174
[TBL] [Abstract][Full Text] [Related]
17. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers.
Brooks TW; Creekmore FM; Young DC; Asche CV; Oberg B; Samuelson WM
Pharmacotherapy; 2007 May; 27(5):684-90. PubMed ID: 17461703
[TBL] [Abstract][Full Text] [Related]
18. Comparison of bronchodilator responsiveness in asthma and chronic obstructive pulmonary disease.
Chhabra SK; Bhatnagar S
Indian J Chest Dis Allied Sci; 2002; 44(2):91-7. PubMed ID: 12026258
[TBL] [Abstract][Full Text] [Related]
19. Detection of COPD in a high-risk population: should the diagnostic work-up include bronchodilator reversibility testing?
Kjeldgaard P; Dahl R; Løkke A; Ulrik CS
Int J Chron Obstruct Pulmon Dis; 2015; 10():407-14. PubMed ID: 25759573
[TBL] [Abstract][Full Text] [Related]
20. Comparison of cerebral blood flow in subjects with and without chronic obstructive pulmonary disease from the population-based Rotterdam Study.
Wijnant SRA; Bos D; Brusselle G; Grymonprez M; Rietzschel E; Vernooij MW; Terzikhan N; Lahousse L
BMJ Open; 2021 Dec; 11(12):e053671. PubMed ID: 34921083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
